British pharmaceutical giant GlaxoSmithKline (GSK) says it plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years.
This includes a new $1.2 billion investment in advanced manufacturing facilities and AI and advanced digital technologies, to deliver new, next-generation biopharma factories and laboratories in the United States.
These investments build on GSK’s strong innovation and manufacturing footprint and capabilities in the United States today, developing and making products in the United States for the United States. [Read more…] about GlaxoSmithKline to invest $30 billion in R&D and manufacturing in the US